Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeFiD: Denosumab for Fibrous Dysplasia/McCune-Albright Syndrome in Adults
2022-002611-29Phase 4Active
- Sponsor
- Leiden University Medical Center
- Start
- Mar 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in fibrous dysplasia and McCune-Albright syndrome (MAS) comparing Denosumab with Placebo (2 arms). Primary endpoint: Maximum pain score change at 6 months. Started Mar 2023; status: active.
02
Drugs
denosumab
03
Conditions
fibrous dysplasiaMcCune-Albright syndrome (MAS)
Beyond the preview
Go deeper on 2022-002611-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-002611-29.